Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Harmonising global approaches to transformative theranostics
This article explores the landscape, regulatory considerations, infrastructural and operational requirements along with future directions for expanding Radiopharmaceuticals and Theranostics therapies into clinical settings.
-
Making early AD trials feasible
Early intervention in neurodegenerative diseases, such as Alzheimer’s, offers the potential to slow or prevent disease progression, and increase success rates for clinical development.
-
The impact of drug pricing and reimbursement on the pharmaceutical industry
Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. Companies must consider price and reimbursement across multiple countries, act early in the development cycle and ensure the evidence required to support their commercial strategy is built into their development plans.
-
Shifting paradigms of clinical trial design accelerate CNS R&D
Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed. Bill Holt outlines how drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.
-
Navigating protocol development in early phase trials
In an ICON survey of 149 biotech professionals, 45% of survey respondents identified protocol design as one the most significant challenges faced when transitioning from preclinical to clinical testing. Here, we discuss considerations for several key elements of protocol development in early phase trials, including selection of healthy volunteers (HVs) or patients, trial design and endpoint selection.
-
The rising impact of biomarkers in early clinical development
Dr. Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
-
Partnering for success in early phase clinical development
Early-phase clinical trials serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market. However, these early stages present significant challenges—nearly half of all drugs entering clinical trials do not make it past phase 1. With the average phase 1 trial costing millions of dollars and consuming valuable time, biotechs have little room for error. This article discusses how partnering with a CRO can benefit a small biotech - helping to fill the gaps in knowledge, resources infrastructure.
-
Precision Medicine: Pitfalls and Potential
In this article, Anna Guildford, Senior Consultant, KCR, shares insights on how precision medicine is discussed as a novel approach using genetic and health data to tailor treatments, improving patient outcomes and reducing adverse effects.
-
Building on biotech confidence with strategic R&D
In this article from BIO-IT World, Dr. Chris Smyth, President of ICON Biotech outlines how despite ongoing challenges, biotech companies can build on growing market confidence by utilising their capital in the most effective and efficient way possible, through improved trial designs, timelines and data-responsive strategies.
-
US Pharma and Biotech Summit 2024: Evolving clinical research
In this news article, Applied Clinical Trials reports on ICON CEO Steve Cutler’s discussion at the FT US Pharma and Biotech Summit. Topics addressed included the evolution of the CRO and sponsor relationship, the potential of AI in the clinical development space, and how ICON is helping customers build strong portfolios.
